Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome.

Elizabeth L Berg Stela P Petkova Heather A BornAnna AdhikariAnne E Anderson Jill L Silverman

Published in: Molecular autism (2021)

Despite a few observed effects of IGF-2, our results taken together indicate that IGF-2 treatment does not profoundly improve behavioral deficits in mouse or rat models of AS. These findings shed cautionary light on the potential utility of acute systemic IGF-2 administration in the treatment of AS.

Keyphrases

traumatic brain injury
growth hormone
liver failure
combination therapy
risk assessment
signaling pathway
case report
respiratory failure
mechanical ventilation